Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.52 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384629 | 0.86 | USP28 (0.56) | PTGESSLC6A4MAOBUSP28USP25 | |
| SCHEMBL31053215 | 0.86 | PTGES (0.46) | PTGESSLC6A4MAOBUSP28USP25 | |
| SCHEMBL31644088 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBUSP28USP25HTT | |
| SCHEMBL368071 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBUSP28USP25HTT | |
| SCHEMBL6700367 | 0.84 | LMNA (0.55) | MAOBALDH1A1LMNAAPPMCL1 | |
| SCHEMBL3918953 | 0.83 | SLC6A4 (0.58) | SLC6A4CCR5 | |
| SCHEMBL3929012 | 0.83 | CYP1A2 (0.61) | SLC6A4MAOB | |
| SCHEMBL3918664 | 0.83 | MAOB (0.51) | SLC6A4MAOBCCR5ALDH1A1 | |
| Benzyl Bromide SCHEMBL5708217 | 0.82 | SLC6A4 (0.52) | SLC6A4CCR5PTGER1 | |
| SCHEMBL4434864 | 0.82 | SLC6A4 (0.56) | SLC6A4MAOBUSP28USP25HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4509500-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119173510-A | Hydroxy amide derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| CN-111217811-B | Fused tricyclic compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023222115-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-110028976-B | Compound, liquid crystal composition, liquid crystal display element and liquid crystal display | 石家庄诚志永华显示材料有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111217811-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | PTGES 664/4885SLC6A4 4776/4885MAOB 2485/4885 |
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | PTGES 2212/4885SLC6A4 3392/4885MAOB 1446/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | PTGES 912/4885SLC6A4 129/4885MAOB 18/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | PTGES 664/4885SLC6A4 4776/4885MAOB 2485/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | PTGES 3649/4885SLC6A4 1652/4885MAOB 2206/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | PTGES 3501/4885SLC6A4 406/4885MAOB 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.